Stopping Mutant KRAS Could Lead to Enhanced Therapies for Pancreatic Cancer

Published by W Butcher on

If clinicians could stop mutations of the KRAS gene in pancreatic cancer – which happens in more than 90 percent of pancreatic cancer cases and drastically reduces response to immunotherapy – the chances of improving treatment for this deadly form of cancer would be increased. A collaborative study by Stony Brook University scientists, published in Nature Communications, takes an initial step toward better understanding how KRAS drives immune evasion and demonstrates a lowering of the KRAS activity resulting in a more favorable immune environment to fight cancer.

Read More…

Categories: Uncategorized

0 Comments

Leave a Reply

Avatar placeholder

Your email address will not be published.